Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Knightscope
Sponsored
content by Knightscope
MA
MarketJar
Community Contributor
The Next Phase of Defense AI: A Robotic Response to America’s Security Gaps
Autonomous systems are no longer just a futuristic vision — they’re fast becoming an essential layer of national security. As AI reshapes everything from finance to warfare, physical security remains one of the most under-addressed frontiers.
View narrative
US$12.00
FV
51.2% undervalued
intrinsic discount
22.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
1
users have commented on this narrative
23
users have followed this narrative
New
narrative
Figma
TI
TickerTickle
Community Contributor
Figma (FIG): The S&P 500’s Design Standard Turning Into an All-in-One Platform
Watching Figma Grow Up I’ve been using Figma almost every single day for the past five years. As a product designer, it’s been my main tool for designing interfaces, testing and prototyping ideas, and also for working together with teams in different countries and time zones.
View narrative
US$65.70
FV
6.7% overvalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
Updated
narrative
Sleep Cycle
MA
Mandelman
Community Contributor
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Update Q1 2025 (updated 250510) The latest user‐growth data suggest headwinds for top-line revenue, but management’s active repricing initiatives should help offset this. By combining modest user gains with targeted price increases, the company can still drive overall revenue growth.
View narrative
SEK 38.04
FV
24.6% undervalued
intrinsic discount
3.15%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
24
users have followed this narrative
Updated
narrative
JB Hi-Fi
RO
Robbo
Community Contributor
Has JB Hi-Fi Lost Its Point of Difference?
I may be showing my age here, but I feel that a decade or so ago, shopping at JB Hi-Fi was a different experience. There seemed to be a deliberate policy of employing sales staff from alternative subcultures, which gave the stores a unique, edgy vibe.
View narrative
AU$76.00
FV
51.4% overvalued
intrinsic discount
-0.45%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
1
users have commented on this narrative
5
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Exelixis
AN
AnalystLowTarget
Consensus Narrative from 19 Analysts
Regulatory Uncertainty And 340B Pressures Will Erode Oncology Margins
Key Takeaways Increasing regulatory scrutiny, payer discounts, and reliance on a single franchise threaten margins, revenue stability, and overall profitability. Rising R&D costs and intensifying competition in oncology create risks to market share, product relevance, and sustained earnings growth.
View narrative
US$36.00
FV
6.5% overvalued
intrinsic discount
4.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
17 days ago
author updated this narrative
FMC
AN
AnalystLowTarget
Consensus Narrative from 18 Analysts
Rising Agrochemical Bans And Shifting Trends Will Erode Market Viability
Key Takeaways Regulatory bans and shifts to organic farming are shrinking demand and challenging FMC's conventional crop protection business, intensifying margin and growth pressures. Limited R&D spending and reliance on aging specialty products expose FMC to competitive, patent, and innovation risks, threatening future earnings and market position.
View narrative
US$37.00
FV
6.9% overvalued
intrinsic discount
2.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
17 days ago
author updated this narrative
MKS
AN
AnalystLowTarget
Consensus Narrative from 13 Analysts
Tariff Hikes And Integration Woes Will Erode Semiconductor Margins
Key Takeaways Rising trade barriers and geopolitical instability are disrupting global supply chains, eroding margins, and limiting future earnings and cash flow potential. Customer localization, integration issues, and in-house equipment development threaten MKS's market share, long-term revenue growth, and margin sustainability.
View narrative
US$92.09
FV
15.7% overvalued
intrinsic discount
4.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
17 days ago
author updated this narrative
Open Text
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Legacy Decline And Acquisition Risks Will Shadow Future Value
Key Takeaways Persistent weakness in legacy products, modest cloud growth, and intense price competition threaten long-term revenue and margin expansion. Heavy dependence on acquisitions and pressures from regulatory, technological, and hyperscaler shifts heighten operational and strategic risks.
View narrative
US$28.00
FV
15.1% overvalued
intrinsic discount
0.075%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
17 days ago
author updated this narrative
Knight-Swift Transportation Holdings
AN
AnalystLowTarget
Consensus Narrative from 20 Analysts
Declining Freight Demand And Cost Pressures Will Overwhelm Profit Margins
Key Takeaways Shifting market dynamics and competition from e-commerce and tech-driven logistics platforms threaten core revenue streams and undermine pricing power. Rising environmental regulation and complex acquisitions elevate costs and operational risks, constraining cash flow, profitability, and investment flexibility.
View narrative
US$43.00
FV
3.4% overvalued
intrinsic discount
4.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
17 days ago
author updated this narrative
Antero Resources
AN
AnalystLowTarget
Consensus Narrative from 21 Analysts
Decarbonization And ESG Limits Will Squeeze US Gas Margins
Key Takeaways Long-term demand and pricing for natural gas and NGLs are at risk due to decarbonization, renewables adoption, and market volatility, impacting revenue and earnings stability. Increasing regulatory, ESG, and regional pressures could raise costs, restrict production, and constrain future growth and profitability.
View narrative
US$31.07
FV
0.2% overvalued
intrinsic discount
3.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
17 days ago
author updated this narrative
Chord Energy
AN
AnalystLowTarget
Consensus Narrative from 15 Analysts
Global Decarbonization And Williston Basin Risks Will Depress Margins
Key Takeaways Rapid adoption of renewables, stricter regulation, and new technologies threaten Chord Energy's revenue growth and long-term earnings stability. High operational exposure in one region and limited access to capital may further constrain production and increase financing challenges.
View narrative
US$105.00
FV
0.9% overvalued
intrinsic discount
-8.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
17 days ago
author updated this narrative
Teleflex
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Rising Cost Pressures And Supply Risks Will Shrink Healthcare Prospects
Key Takeaways Margin pressure and reduced revenue outlook stem from cost containment, supply chain risks, and heavy dependence on commoditized, mature product lines. Shifts toward telemedicine and operational challenges from acquisitions threaten long-term growth and amplify risks to earnings and profitability.
View narrative
US$120.00
FV
6.0% overvalued
intrinsic discount
6.09%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
17 days ago
author updated this narrative
Eastman Chemical
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
Asian Dumping And Tariffs Will Crimp Chemical Margins
Key Takeaways Exposure to trade restrictions, anti-plastic mandates, and aggressive Asian competition threatens demand, pricing power, and global market share across key business segments. Substantial capital and regulatory costs, environmental liabilities, and declining margins may limit cash flow, earnings growth, and overall financial resilience.
View narrative
US$60.00
FV
13.8% overvalued
intrinsic discount
-1.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
17 days ago
author updated this narrative
Value any company in seconds
Popular companies